Navigation Links
Cancer Vaccines: From First-in-Class to Best-in-Class?
Date:4/9/2013

tion through Close Mechanistic Approximation between Myeloma Drugs 465
Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma 466
Table 97: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer 467
Table 98: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 468
Table 99: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer 469
Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma 470
Table 101: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer 471
Table 102: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 472
Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer 473
Table 104: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 474
Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Peritoneal Cancer 475
Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer 476
Table 107: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 477
Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 479
Table 109: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer 480
Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 481
Table 111: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Sarcoma (general) 482
Table 112: Target Strategy Development Profiles
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
2. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
3. Take the Skyhook Challenge and Help Beat Blood Cancer
4. Merrimack Pharmaceuticals Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
5. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
6. Penn Medicines New Center For Personalized Diagnostics Unlocks Cancers Secrets
7. Cerulean Pharma to Present Data on CRLX101s HIF-1a Inhibition at the American Association for Cancer Research Annual Meeting
8. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
9. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
10. National Cancer Organizations Issue Joint Statement On Devastating Impact Of Sequestration
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/22/2014)... Association for Molecular Pathology (AMP) released a report ... on recommendations for a molecular diagnostics curriculum ... education. The report was prepared by the Medical ... AMP Training and Education Committee. "Our goal was ... medical laboratory scientists appropriately in order to manage ...
(Date:4/22/2014)... the standard measurement for assessing glycemic control over time ... typically measured every few months in a laboratory, but ... estimates A1c using self-monitored blood glucose (SMBG) readings, as ... DTT ), a peer-reviewed journal from Mary Ann Liebert, ... DTT website at http://www.liebertpub.com/dtt . , ...
(Date:4/22/2014)... To help rein in massive health care spending, a ... urgently find ways to incentivize pharmaceutical companies and device ... Instead of examining existing medical technologies and their use, ... affect what drugs and medical devices get created in ... health care spending with as little loss of health ...
(Date:4/22/2014)... ARBOR, Mich. Nearly 7 in 10 Americans ... a new national survey by researchers at the University ... with children under the age of 18 at home, ... more likely than other adults to support universal coverage ... appear in the Journal of the American Medical ...
(Date:4/22/2014)... news release is available in German . ... Perutz Laboratories of the University of Vienna and the Medical ... have now shown how double stranded RNA, such as viral ... cell. During the immune response against viral infection, the protein ... There it modifies viral RNA to inhibit reproduction of the ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:How the body fights against viruses 2Health News:How the body fights against viruses 3
... The Reeve Foundation debuts new national ad campaign giving ... HILLS, N.J., Nov. 3 The Christopher & Dana ... advertising,campaign. The campaign presents an edgier side of the ... life is like through the eyes of,someone living with ...
... critical need to review current treatment strategies for the ... to a series of international papers in the November ... with severe disability, unmet treatment need and little clinical ... Professor David W Dodick from the Mayo Clinic College ...
... 3 Pregis Corporation, a leading,international manufacturer, ... specialty packaging solutions, will conduct an investor,conference ... results on Friday,November 14, 2008 at 10:00 ... 617-614-4909; Participant Passcode: 68623125. A replay of,the ...
... crucial element in hip,fracture recovery, ROSEMONT, Ill., ... fracture are referred to their primary care physicians ... published in the,November 2008 issue of The Journal ... an osteoporosis management program initiated by an,orthopaedic surgeon ...
... LifeNet Health,a leading allograft bio-implant company, ... United States Food and Drug Administration (FDA) ... technology., LifeNet Health received clearance for ... donor cells from cardiovascular tissues,while retaining the ...
... (Nasdaq: BMRN ) announced today the initiation ... with the lysosomal storage disease,Mucopolysaccharidosis Type IVA (MPS ... augment available data on the disease by measuring ... patients.,BioMarin expects to follow the MorCAP program with ...
Cached Medicine News:Health News:Christopher & Dana Reeve Foundation Launches First-Ever National Advertising Campaign 2Health News:Urgent need for research into the best treatment for medication overuse headaches 2Health News:Urgent need for research into the best treatment for medication overuse headaches 3Health News:Urgent need for research into the best treatment for medication overuse headaches 4Health News:Treating Osteoporosis After Hip Fracture 2Health News:Treating Osteoporosis After Hip Fracture 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 2Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 3Health News:BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: